News Releases

17 Apr '23
Alvotech has been informed by the U.S. Food and Drug Administration (FDA) that the responses provided to the FDA Form 483 on April 3, 2023, following the conclusion of the reinspection of the company’s Reykjavik facility on March 17, 2023, are currently under review.
28 Mar '23
Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the Board of Directors has resolved to increase the Company´s share capital by an amount of
Displaying 51 - 60 of 151